We are live on ! Find out more
HQL

abrdn Life Sciences Investors

78 hedge funds and large institutions have $74.4M invested in abrdn Life Sciences Investors in 2023 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 34 increasing their positions, 19 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

79% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 19

14% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 7

4% more capital invested

Capital invested by funds: $71.9M → $74.4M (+$2.54M)

0.21% more ownership

Funds ownership: 20.76%20.97% (+0.21%)

0% more funds holding

Funds holding: 7878 (0)

Holders
78
Holders Change
Holders Change %
0%
% of All Funds
1.22%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
8
Increased
34
Reduced
19
Closed
7
Calls
Puts
Net Calls
Net Calls Change

HQL Hedge Fund Activity: Q2 2023 in Review

78 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q2 2023, worth a combined $74.4M — up 3.5% from $71.9M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new HQL positions and 7 closed out — a net gain of 1 holder — while 34 added to existing stakes and 19 trimmed.

The largest buyer was RPO LLC, opening a new position worth an estimated $2.57M. The largest seller was Raymond James & Associates, cutting an estimated $2.01M.

  • 78 institutional investors held abrdn Life Sciences Investors (HQL) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $74.4M of abrdn Life Sciences Investors stock for Q2 2023, up 3.5% quarter-over-quarter.
  • 8 funds opened new abrdn Life Sciences Investors positions in Q2 2023 and 7 closed out, a net change of +1 holder.
  • The largest abrdn Life Sciences Investors buyer in Q2 2023 was RPO LLC, an estimated $2.57M added.
  • The largest abrdn Life Sciences Investors seller in Q2 2023 was Raymond James & Associates, an estimated $2.01M sold.

Based on aggregated 13F filings for Q2 2023.